Hospital Acquired Infections (HAI) Diagnostics Market - By Product (Reagents, Analyzers), By Test Type (Traditional Diagnostic Test, Molecular Diagnostic Assay, Immunoassays, Mass Spectrometry), By Infection Type, By End-use, & Forecast, 2023 – 2032

Hospital Acquired Infections (HAI) Diagnostics Market Size

Hospital Acquired Infections Diagnostics Market size was valued at around USD 4.5 billion in 2022 and is estimated to register around 8% CAGR between 2023 and 2032. Healthcare facilities are increasingly prioritizing infection control practices to prevent and reduce hospital acquired infections rates. This focus has led to the adoption of advanced diagnostics for early detection and surveillance of HAIs, facilitating precise intervention and prevention strategies. Molecular diagnostics, such as PCR and next-generation sequencing have improved the sensitivity and specificity of HAI detection.
 

Rapid diagnostic tests have also gained traction due to their quick turnaround time and ease of use. There is a growing trend towards point-of-care testing for HAI diagnostics. POCT enables rapid on-site testing, reducing turnaround time and facilitating prompt decision-making. It is particularly beneficial in emergency departments, intensive care units, and other critical care settings. As healthcare costs continue to rise, there is a growing emphasis on cost-effective HAI diagnostics. Manufacturers are developing affordable and easy-to-use diagnostic solutions that offer accurate results while minimizing healthcare expenditure. Thus, the technological advancements, increased awareness, and government initiatives among others are expected to drive hospital acquired infections diagnostics market growth, leading to improved patient outcomes and reduced healthcare-associated infections.
 

The hospital acquired infections (HAI) diagnostics includes diagnostic tests and devices used for the detection and monitoring of infections that are acquired in healthcare settings such as hospitals, clinics, and long-term care facilities. HAI also known as nosocomial infections, that patients acquire during the course of receiving healthcare treatment for other conditions. 
 

However, the lack of awareness regarding hospital-acquired infections in low and middle-income nations is a significant issue that may impede the market revenue. Many healthcare facilities in low and middle-income nations face resource constraints, including limited funding, inadequate staffing, and insufficient infrastructure. These limitations can impede efforts to implement robust infection control programs and educate healthcare workers and patients about HAIs. Healthcare workers in low and middle-income nations may have limited access to training and educational programs focused on infection control and prevention of HADs. Furthermore, in resource-constrained settings, hospital-acquired infections may receive less attention and resources in comparison, leading to lower awareness levels.
 

COVID-19 Impact

The impact of COVID-19 on the hospital acquired infections (HAI) diagnostics market had been significant. Initially, the focus of healthcare providers and diagnostic companies shifted towards managing the COVID-19 pandemic, resulting in a temporary disruption in routine diagnostic testing for HAIs. Resources such as personnel, laboratory space, and supplies were redirected to COVID-19 testing, leading to a decreased emphasis on HAI diagnostics. However, the healthcare industry had started to regain its focus on managing HAIs, as the understanding of COVID-19 improved and testing capacities expanded. The pandemic had also highlighted the importance of infection control measures and the need for effective HAI diagnostics to prevent and control the spread of infections within healthcare settings. The COVID-19 pandemic had accelerated the adoption of innovative diagnostic technologies and solutions in the HAI Diagnostics market.
 

Hospital Acquired Infections Diagnostics Market Trends

The technological advancements in the hospital acquired infections HAI diagnostics market aimed at improving the accuracy, speed, and efficiency of HAI detection. Molecular diagnostic techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) have revolutionized the detection of HAIs. These techniques can rapidly detect and identify the DNA or RNA of specific pathogens, allowing for early and accurate diagnosis. They are particularly useful for detecting antibiotic-resistant organisms and identifying outbreaks. Next-Generation Sequencing (NGS) technologies have greatly enhanced ability to identify and characterize pathogens responsible for HAIs. NGS allows for the sequencing of entire microbial genomes, providing detailed information about the genetic makeup of the infecting organisms. This can help in tracking the transmission of infections, identifying resistant strains, and optimizing treatment strategies.
 

Point-of-care testing (POCT) devices are becoming increasingly important in the early detection of HAIs. These portable and user-friendly devices can deliver rapid test results at the patient's bedside, eliminating the need for sample transportation and centralized laboratory testing. POCT allows for timely interventions, reduces turnaround time, and facilitates prompt decision-making for infection control. Moreover, AI algorithms are assisting to analyze large datasets of patient information, laboratory results, and epidemiological data to identify patterns and predict the risk of HAIs. AI-powered systems can help in early detection, outbreak prediction, and optimization of infection control measures. As a result, these advancements in HAI diagnostics have the potential to improve patient outcomes, reduce healthcare costs, and enhance infection control measures in healthcare facilities.
 

Hospital Acquired Infections (HAI) Diagnostics Market Analysis

Based on product, the market is segmented as reagents and analyzers. The reagents held the dominant hospital acquired infections diagnostics market share in 2022 and was valued at over USD 2.9 billion. The demand for reagents used in hospital acquired infections is generally driven by the need for accurate and timely detection of infections in healthcare facilities. Market players are designing highly sensitive & specific infectious agents associated with HAIs. This allowing accurate detection even at low concentrations, increasing the chances of early and reliable diagnosis. These reagents can be integrated into automated diagnostic systems, improving efficiency and reducing human errors. Automated tests can process a large number of samples quickly, making them suitable for screening purposes or in busy healthcare settings.
 

In HAI diagnostics tests, reagents can be modified to target specific pathogens commonly associated with hospital-acquired infections such as methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. difficile), or multidrug-resistant Gram-negative bacteria. These reagents can be used in various diagnostic methods including polymerase chain reaction (PCR), immunoassays, or nucleic acid amplification tests (NAATs) to identify the presence of these pathogens or their associated biomarkers. As a result, by utilizing reagents in HAI diagnostics tests, healthcare professionals can quickly and accurately identify infections, initiate appropriate treatments, and implement infection control measures to prevent the spread of HAIs in healthcare settings.
 

Based on test type, the hospital acquired infections diagnostics market is segmented as traditional diagnostic test, molecular diagnostic assay, immunoassays, mass spectrometry, and others. The immunoassays segment held a dominant market share in 2022 and was valued at around USD 1.7 billion. Immunoassays play a crucial role in diagnosing various medical conditions including hospital acquired infections. Immunodiagnostic tests for HAIs can help identify specific pathogens responsible for the infection, monitor the patient's immune response, and determine appropriate treatment strategies. The most widely used immunodiagnostic tests used in HAI diagnostics include enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), immunofluorescence assay (IFA), and serological testing among others.
 

ELISA is a widely used immunological assay that detects and quantifies antibodies or antigens in a sample. It can be employed to detect specific pathogens or their antibodies in patient samples, aiding in the diagnosis of HAIs. Serological tests detect the presence of antibodies in a patient's blood. They can be used to determine if a patient has been exposed to a particular pathogen, indicating a current or previous infection. Serological tests are valuable for monitoring the immune response and assessing the prevalence of HAIs within a healthcare facility. Thus, Healthcare professionals and clinical laboratories rely on these tests to diagnose HAIs accurately, initiate timely treatment, and implement infection control measures to prevent further transmission.  Thus, healthcare professionals and clinical laboratories rely on these tests to diagnose HAIs accurately, initiate timely treatment, and implement infection control measures to prevent further transmission.
 

Based on test type, the hospital acquired infections diagnostics market is segmented as urinary tract infections (UTIs), surgical site infections (SSIs), respiratory infections, bloodstream infections, gastrointestinal infections, and others. The urinary tract infections (UTIs) segment held a dominant market share in 2022 and was valued at around USD 1.4 billion. Urinary tract infections (UTIs) are one of the most prevalent HAIs, accounting for a significant proportion of infections acquired in healthcare settings. Diagnostics tests play a crucial role in identifying and managing UTIs acquired in hospitals. Diagnostics tests for UTIs can help in the early detection of infections, allowing healthcare providers to initiate appropriate treatment promptly.
 

Early identification can prevent the infection from spreading and causing complications. UTIs can be caused by various pathogens, including bacteria, viruses, and fungi. Diagnostics tests such as urine culture and sensitivity testing can accurately identify the specific pathogen causing the infection. Some UTIs can be recurrent, especially in healthcare settings. Diagnostics tests can help identify underlying causes or risk factors contributing to recurrent infections such as anatomical abnormalities or indwelling catheters. Conclusively, diagnostics tests for UTIs offer several advantages including early detection, accurate pathogen identification, antibiotic susceptibility testing, prevention of recurrent infections, and infection control among others. As a result, these tests play a vital role in the management and prevention of UTIs acquired in hospitals.
 

Based on end-use, the hospital acquired infections diagnostics market is segmented as hospitals, diagnostic laboratories, research institute, and others. The hospitals segment held significant share in 2022 and is projected to reach more than USD 4.8 billion by the end of 2032. The soaring use of novel immunodiagnostic tests in hospital settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of kits for performing these tests with proven accuracy is set to drive product preference in hospitals.
 

Growing prevalence of hospital acquired infections and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment growth positively. Furthermore, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals. As a result, accessibility to an effective diagnosis coupled with the rising prevalence of hospital acquired infections and associated conditions will boost the patient visits to hospitals, thereby propelling the segment revenue growth.
 

U.S. hospital acquired infections diagnostics market with a significant market share in 2022 and is anticipated to expand at a considerable pace to reach around USD 4.2 billion by 2032. This dominant market share is attributable to the increasing prevalence of HAI, emphasis on infection control & prevention, and technological advancements among others. Healthcare-associated infections remain a significant concern in the U.S., leading to increased demand for diagnostic tests that can quickly and accurately detect and identify pathogens responsible for infections.
 

Hospital Acquired Infections (HAI) Diagnostics Market Share

Some of the major market players operating in the hospital acquired infections diagnostics market are:

• Abbott Laboratories
• Bayer
• Becton Dickinson And Company
• Biomérieux
• Danaher Corporation 
• Ecolab

Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.
 

Hospital Acquired Infections (HAI) Diagnostics Industry News:

• In February 2023, Thermo Fisher Scientific partnered with Mylab Discovery Solutions to launch RT- PCR kits for infectious diseases in India. As per the company, highly accurate and effective diagnostic tests such as RT-PCR will help in significant reduction of the burden of these diseases in India. Such strategic moves will assist Thermo Fisher to develop high quality molecular diagnostics kits for patients around the world.
   
• In September 2021, Roche launched diagnostic test panels to detect respiratory illnesses. The three new respiratory test panels can be run together or alone using one patient sample. It uses a use a real-time PCR nucleic acid amplification method to detect specific DNA sequences obtained after extraction. This product launch helped the company to expand the availability of these tests beyond CE markets in the future.
   

Hospital acquired infections (HAI) diagnostics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (Units) from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product

• Reagents
• Analyzers

By Test Type

• Traditional Diagnostic Test
• Molecular Diagnostic Assay
• Immunoassays
• Mass Spectrometry
• Others

By Infection Type

• Urinary Tract Infections (UTIs)
• Surgical Site Infections (SSIs)
• Respiratory Infections
• Bloodstream Infections
• Gastrointestinal Infections
• Others

By End-use

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
• The Netherlands
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Indonesia
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Iran